Market Access News | pharmaphorum

News

NICE says Boehringer stroke drug 'could save millions'

In new guidance, NICE has cleared NHS use of Boehringer Ingelheim's clot-busting therapy Metalyse as a treatment for acute ischaemic stroke in adults.

News

CVS Caremark president David Joyner, Express Scripts president Adam Kautzner, and OptimRx chief executive Patrick Conway

PBMs under the cosh at House hearing on drug pricing

The top three pharmacy benefit managers in the US felt the heat at a hearing of the House Oversight Committee, as lawmakers grilled executives over their business practices and accused them

News

J&J files to expand label of depression drug Spravato

Johnson & Johnson has filed for FDA approval of its antidepressant nasal spray Spravato, hoping to make it the first standalone treatment for adults with treatment-resistant depression

News

Valneva gets $41m grant to roll out chikungunya vaccine

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life

News

NICE backs first 'take at home' prostate cancer pill

Thousands of men in the UK with advanced hormone-sensitive prostate cancer could soon be eligible for an oral therapy – Accord Healthcare's Orgovyx – that can be taken at home rather than r

News

Jennifer Taubert, chair of J&J's worldwide innovation group

J&J IRA pricing offer is in, as it sticks with 2025 guidance...

Johnson & Johnson has three of its top-selling drugs in Medicare pricing negotiations – Stelara, Xarelto, and Imbruvica – but has said it does not expect a major hit to its finances nex

NICE says Boehringer stroke drug 'could save millions'

PBMs under the cosh at House hearing on drug pricing

J&J files to expand label of depression drug Spravato

Valneva gets $41m grant to roll out chikungunya vaccine

NICE backs first 'take at home' prostate cancer pill

J&J IRA pricing offer is in, as it sticks with 2025 guidance...

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks